SS-31 peptide cycling claims: what TikTok gets wrong

What did @smoneyyz actually say?

The creator laid out a personal SS-31 cycling protocol, describing 10 days at 1mg/day followed by 5 days at 2mg/day. They credited the peptide with reducing brain fog, fixing "executive dysfunction related to ADHD," and helping them transition off another compound called RETA. They also claimed SS-31 is "FDA approved under the name Alamipurtide" for mitochondrial myopathy, and that it "repairs the inner mitochondrial membrane" and "boosts ATP production." The video ends with a link to purchase in bio, framed as research entertainment only.

That disclaimer does not change the fact that the creator is describing a specific dosing protocol, attributing personal health outcomes to it, and directing viewers to a purchase link. The framing matters less than the function.

Does the science back this up?

Some of it, yes, but mostly in animal models and small early-phase trials, not in healthy adults self-dosing for biohacking purposes. SS-31, also known as Elamipretide (not Alamipurtide), is a mitochondria-targeting tetrapeptide that has shown real, documented effects on cardiolipin stabilization in the inner mitochondrial membrane. The ATP production angle has some support.

Szeto et al. (2014, Biochimica et Biophysica Acta) demonstrated that SS-31 targets cardiolipin, stabilizes cytochrome c, and reduces electron leak, which does mechanistically support claims about ATP efficiency and reactive oxygen species reduction. That part is not fabricated. But the jump from mouse mitochondrial models to "fixes ADHD" in a healthy adult is a significant leap with no peer-reviewed human data to land on. A small Phase II trial in heart failure (Daubert et al., 2017, JACC: Basic to Translational Science) showed modest improvement in mitochondrial function, but this was an IV-administered compound in cardiac patients, not a subcutaneous self-administered protocol.

What did they get wrong (or right)?

The FDA approval claim is the most significant error here. The creator says SS-31 is "FDA approved under the name of Alamipurtide." This is wrong on two counts. First, the drug name is Elamipretide, not Alamipurtide. Second, as of this writing, Elamipretide (Stealth BioTherapeutics' drug, formerly MTP-131) did not receive FDA approval. A Phase III trial for Barth syndrome was conducted, but the compound has not cleared FDA approval. Calling a non-approved investigational drug "FDA approved" is a material factual error that could mislead viewers into thinking they are using something with a validated safety profile.

What they got right: the basic mitochondrial mechanism is directionally accurate. Cardiolipin targeting, ROS reduction, and the concept of preparing mitochondria before running other interventions are not nonsense. The acknowledgment of fatigue as a reported side effect is also consistent with anecdotal reports in research communities.

What remains unverifiable: the ADHD executive function benefit, the neuroplasticity claims in humans, and the specific protocol dosing have no controlled human trial support.

What should you actually know?

SS-31 is a legitimate research compound with a real mechanistic basis, but it is not FDA approved for any condition, and using it outside a clinical trial means operating without established human dosing data. The compounded peptide available through gray-market research chemical vendors is not the same as the pharmaceutical-grade compound used in trials, and the route of administration, purity, and bioavailability are all unknowns.

The creator's claim that SS-31 "could help repair organ damage" and reduce Alzheimer's is speculative at best. A 2018 study by Bhatt et al. (Redox Biology) showed SS-31 attenuated cognitive decline in aging mice, but mice are not people, and no human Alzheimer's trial has produced approvals or strong clinical signals.

The suggestion to "take as much as you can essentially afford" is not a dosing philosophy with any clinical basis. It is also worth noting that the creator is directing viewers to a purchase link while describing this as entertainment. That tension should not be invisible to the audience.